NO972426D0 - Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose - Google Patents

Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose

Info

Publication number
NO972426D0
NO972426D0 NO972426A NO972426A NO972426D0 NO 972426 D0 NO972426 D0 NO 972426D0 NO 972426 A NO972426 A NO 972426A NO 972426 A NO972426 A NO 972426A NO 972426 D0 NO972426 D0 NO 972426D0
Authority
NO
Norway
Prior art keywords
osteoporosis
prevention
treatment
triarylethylene
derivatives
Prior art date
Application number
NO972426A
Other languages
English (en)
Other versions
NO972426L (no
Inventor
Alan Joseph Bitonti
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/531,885 external-priority patent/US5691384A/en
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of NO972426D0 publication Critical patent/NO972426D0/no
Publication of NO972426L publication Critical patent/NO972426L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO972426A 1994-11-29 1997-05-28 Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose NO972426L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34611194A 1994-11-29 1994-11-29
US08/531,885 US5691384A (en) 1994-11-29 1995-10-11 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
PCT/US1995/013873 WO1996016646A1 (en) 1994-11-29 1995-10-27 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis

Publications (2)

Publication Number Publication Date
NO972426D0 true NO972426D0 (no) 1997-05-28
NO972426L NO972426L (no) 1997-07-29

Family

ID=26994698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972426A NO972426L (no) 1994-11-29 1997-05-28 Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose

Country Status (12)

Country Link
US (1) US5693674A (no)
EP (1) EP0794771A1 (no)
JP (1) JPH10509962A (no)
CN (1) CN1167437A (no)
AU (1) AU707290B2 (no)
CA (1) CA2206422A1 (no)
FI (1) FI972235A0 (no)
HU (1) HUT77603A (no)
IL (1) IL116142A0 (no)
MX (1) MX9703944A (no)
NO (1) NO972426L (no)
WO (1) WO1996016646A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
MX2008014825A (es) * 2006-05-22 2008-12-01 Hormos Medical Ltd Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana.
KR101510646B1 (ko) * 2007-02-14 2015-04-10 호르모스 메디칼 리미티드 치료적으로 유용한 트리페닐부텐 유도체의 제조 방법
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
CN105012282A (zh) 2008-07-02 2015-11-04 不列颠哥伦比亚癌症局分支机构 二缩水甘油醚衍生物治疗剂和它们的使用方法
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
ES2907708T3 (es) * 2015-01-13 2022-04-26 British Columbia Cancer Agency Branch Compuestos heterocíclicos para obtención de imágenes y tratamiento del cáncer y métodos para su uso
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
SG11202103325WA (en) 2018-10-18 2021-05-28 Essa Pharma Inc Androgen receptor modulators and methods for their use
US20210323931A1 (en) 2020-04-17 2021-10-21 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
US3247252A (en) * 1962-11-14 1966-04-19 Richardson Merrell Inc Beta-dialkylaminoethylamino-triphenylethanols, -ethanes, and -ethenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1128379A (en) * 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
US4001229A (en) * 1974-04-04 1977-01-04 Mead Johnson & Company Alkanesulfonamido triphenylethylenes
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
JPH06312930A (ja) * 1993-04-30 1994-11-08 Kuraray Co Ltd 骨粗鬆症治療剤
US5525633A (en) * 1993-09-24 1996-06-11 Merrell Dow Pharmaceuticals Inc. Triaryl-ethylene derivatives
ZA956029B (en) * 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss

Also Published As

Publication number Publication date
JPH10509962A (ja) 1998-09-29
AU4196796A (en) 1996-06-19
EP0794771A1 (en) 1997-09-17
WO1996016646A1 (en) 1996-06-06
US5693674A (en) 1997-12-02
CN1167437A (zh) 1997-12-10
HUT77603A (hu) 1998-06-29
AU707290B2 (en) 1999-07-08
FI972235A (fi) 1997-05-27
NO972426L (no) 1997-07-29
CA2206422A1 (en) 1996-06-06
FI972235A0 (fi) 1997-05-27
MX9703944A (es) 1998-05-31
IL116142A0 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
NO981810D0 (no) Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt
NO971015L (no) Forbindelser og metoder for behandling av cancer
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
KR960009070B1 (en) Method and apparatus for wet treatment of solid surfaces
NO992641D0 (no) Blandinger og fremgangsmÕter for behandling eller forhindring av betennelsessykdommer
NO984947D0 (no) Avisingsmiddel og fremgangsmÕte ved anvendelse av dette
HU9802721D0 (en) Method and composition for the treatment and prevention of hyperuricemia
NO972426D0 (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
NO962482D0 (no) Anordning og fremgangsmåte ved behandling av organohalogen forbindelser
EP0800482A4 (en) METHOD AND DEVICE FOR TREATING CONCENTRATED WASTEWATER
DE69515626D1 (de) Plasmabehandlungsverfahren und -vorrichtung
HK1014563A1 (en) Method and apparatus for the surface treatment of parts
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
NO962752D0 (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
NO983512D0 (no) Midler for behandling og forhindring av AIDS
IL120606A0 (en) Apparatus and method for the reduction of snoring
HU9502722D0 (en) Amino-methyl-phosphonic- and amino-methyl-phosphinic-acid derivatives and their use for treating degenerative membrum diseases
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
GB2285441B (en) Method and device for the treatment of water
TW373643U (en) Method and apparatus for the treatment of stainless steel surfaces
AU4521497A (en) Method and apparatus for the treatment of organic matter
NO990283D0 (no) Formulering for behandling og/eller profylakse av demens
NO942686D0 (no) Anvendelse av 3-arylindol- og 3-arylindazolderivater ved behandling av psykoser
IL129431A0 (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
ZA9510062B (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application